Michele Montrone is a Medical Oncologist at IRCCS Istituto Tumori “Giovanni Paolo II” in Bari. After completing a medical degree in 2002, he started a fellowship in Medical Oncology at the University of Bari Medical School the same year. He completed a PhD on “Molecular Diagnostic in Internal Medicine and Oncology” in 2010 due to his interest in HCV-associated lymmphomagenesis and immune-biology in virus-associated lymphoproliferative disorders. In 2007, he performed a research fellowship at CRO National Cancer Center in Aviano (PN), studying an active immunotherapy approach in subset-specific HCV-related Non-Hodgkin’s Lymphomas. Since 2009, Dr. Montrone focused his clinical interest in the field of Thoracic Oncology, first in Taranto, where he was resident physician from 2008 to 2017, and then in Bari. His main research and clinical interests are immunotherapy and novel approaches in non-small cell lung cancer, with particular focus on stage III unresectable disease. He has been involved as a co-investigator in several clinical trials investigating new approaches in the treatment of advanced stage or locally advanced non-small cell lung cancer. He is a co-author of several scientific papers published in peer review journals and a member of the Italian Association of Medical Oncology (AIOM) and the International Association for the Study of Lung Cancer (IASLC).